

Rebecca S Heist

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5935392/publications.pdf>

Version: 2024-02-01

62
papers

7,850
citations

136950

32
h-index

138484

58
g-index

64
all docs

64
docs citations

64
times ranked

9574
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100262.	1.1	7
2	Antiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. <i>European Journal of Cancer</i> , 2022, 166, 112-125.	2.8	4
3	OUP accepted manuscript. <i>Oncologist</i> , 2022, , .	3.7	0
4	Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3318-3328.	7.0	45
5	Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase-Positive Lung Cancer and CNS-Specific Relapse. <i>JCO Precision Oncology</i> , 2022, 6, e2100522.	3.0	8
6	Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRAS ^{G12C} Mutation. <i>New England Journal of Medicine</i> , 2022, 387, 120-131.	27.0	269
7	Abstract CT197: Phase 1b study of LXH254 + trametinib (TMT) in patients (pts) with NRAS-mutant melanoma. <i>Cancer Research</i> , 2022, 82, CT197-CT197.	0.9	0
8	Abstract CT202: A first-in-human phase 1 study of LY3537982, a novel, highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C mutant advanced solid tumors (trial in progress). <i>Cancer Research</i> , 2022, 82, CT202-CT202.	0.9	1
9	Abstract CT033: KontRASt-01: A phase 1b/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors. <i>Cancer Research</i> , 2022, 82, CT033-CT033.	0.9	8
10	Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2996-3004.	7.0	23
11	Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations. <i>Nature Cancer</i> , 2021, 2, 498-502.	13.2	26
12	A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor. <i>Journal of Thoracic Oncology</i> , 2021, 16, 850-859.	1.1	35
13	Acquired Resistance to KRAS ^{G12C} Inhibition in Cancer. <i>New England Journal of Medicine</i> , 2021, 384, 2382-2393.	27.0	482
14	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 6343-6353.	7.0	8
15	Abstract LB056: Accurate detection of MET exon 14 skipping using a liquid biopsy assay in NSCLC patients in the GEOMETRY mono-1 study. , 2021, , .		2
16	Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation. <i>Cancers</i> , 2021, 13, 3572.	3.7	19
17	Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer. , 2021, , .		8
18	Lung cancer. <i>Lancet, The</i> , 2021, 398, 535-554.	13.7	896

#	ARTICLE	IF	CITATIONS
19	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5781-5792.	7.0	30
20	Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification. <i>Journal of Thoracic Oncology</i> , 2020, 15, e8-e10.	1.1	3
21	Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. <i>Cancer Discovery</i> , 2020, 10, 40-53.	9.4	219
22	Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2020, 147, 1963-1969.	5.1	28
23	Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 673-683.	2.3	39
24	Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. <i>Nature Medicine</i> , 2020, 26, 47-51.	30.7	255
25	Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. <i>Cancer Discovery</i> , 2019, 9, 1372-1387.	9.4	158
26	Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. <i>Lung Cancer</i> , 2019, 133, 96-102.	2.0	85
27	Clinical Validation of a Cell-Free DNA Gene Panel. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 632-645.	2.8	15
28	SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 97-104.	1.6	159
29	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. <i>Clinical Cancer Research</i> , 2019, 25, 2699-2707.	7.0	98
30	CMET-22. CAPMATINIB (INC280) IN MET ^{EX14} -MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi56-vi56.	1.2	7
31	Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. <i>Cancers</i> , 2019, 11, 2033.	3.7	26
32	Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 135-140.	1.1	88
33	Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts. <i>Cancer Discovery</i> , 2018, 8, 600-615.	9.4	157
34	Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. <i>Cancer Discovery</i> , 2018, 8, 714-729.	9.4	228
35	Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors Through Longitudinal Analysis of Circulating Tumor DNA. <i>JCO Precision Oncology</i> , 2018, 2018, 1-14.	3.0	86
36	First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2018, 36, 3298-3306.	1.6	88

#	ARTICLE	IF	CITATIONS
37	Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 1675-1684.	1.6	584
38	Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-13.	3.0	17
39	A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxalisib in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2018, 119, 1471-1476.	6.4	74
40	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. <i>Cancer Discovery</i> , 2018, 8, 1529-1539.	9.4	342
41	Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2018, 101, 114-122.	2.8	45
42	Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival. <i>Cancer Epidemiology</i> , 2017, 47, 28-34.	1.9	14
43	Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. <i>JAMA Oncology</i> , 2017, 3, 1043.	7.1	98
44	Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, e155-e157.	1.1	9
45	First-Line Systemic Therapy for Non-Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 59-70.	2.2	9
46	Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase- α -Inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. <i>Clinical Cancer Research</i> , 2017, 23, 5711-5719.	7.0	107
47	MET Exon 14 Skipping in Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2016, 21, 481-486.	3.7	94
48	Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1242-1245.	1.1	140
49	End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations. <i>Journal of Palliative Medicine</i> , 2016, 19, 1316-1319.	1.1	7
50	Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1118-1133.	9.4	919
51	Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. <i>JAMA Oncology</i> , 2016, 2, 541.	7.1	49
52	Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer. <i>Methods</i> , 2015, 83, 118-127.	3.8	33
53	Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558,) Tj ETQq1 1 0.784314 rgB Clinical Oncology, 2015, 33, 2004-2012.	1.6	1,035
54	Genotyping Lung Cancer Is an Investment in the Future. <i>Journal of Clinical Oncology</i> , 2014, 32, 3576-3577.	1.6	6

#	ARTICLE	IF	CITATIONS
55	CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2014, 9, 214-221.	1.1	49
56	Polymorphisms in MicroRNAs Are Associated with Survival in Non-Small Cell Lung Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2503-2511.	2.5	22
57	Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers. <i>Cancer Research</i> , 2014, 74, 3146-3156.	0.9	69
58	Inflammation-Related Genetic Variations and Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving First-Line Chemotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 360-369.	4.7	16
59	Adjuvant Therapy for a 3.9-cm Adenocarcinoma of the Lung. <i>Oncologist</i> , 2013, 18, 1258-1261.	3.7	0
60	FGFR1 Amplification in Squamous Cell Carcinoma of The Lung. <i>Journal of Thoracic Oncology</i> , 2012, 7, 1775-1780.	1.1	197
61	Genetic Changes in Squamous Cell Lung Cancer: A Review. <i>Journal of Thoracic Oncology</i> , 2012, 7, 924-933.	1.1	131
62	SnapShot: Non-Small Cell Lung Cancer. <i>Cancer Cell</i> , 2012, 21, 448-448.e2.	16.8	172